Published in J Exp Med on November 01, 1981
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev (1995) 3.12
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun (1999) 2.20
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog (2007) 1.46
C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest (2000) 1.42
Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun (1992) 1.35
Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun (1986) 1.30
Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae. J Clin Invest (1992) 1.27
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta (2012) 1.20
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J (2007) 1.19
Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog (2009) 1.10
Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A (1997) 1.10
Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae. Infect Immun (1985) 1.08
Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun (2001) 1.05
The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection. Clin Exp Immunol (1983) 1.02
Binding of human C-reactive protein to bacteria. Infect Immun (1982) 1.02
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
Mechanisms of the hepatic acute-phase response during bacterial pneumonia. Infect Immun (2009) 1.00
C-reactive protein protects against preerythrocytic stages of malaria. Infect Immun (1989) 0.99
Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun (2000) 0.97
In vivo turnover studies of C-reactive protein. Clin Exp Immunol (1985) 0.96
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol (2007) 0.95
Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. Biochem J (1985) 0.94
Role of the bacterial cell wall in middle ear inflammation caused by Streptococcus pneumoniae. Infect Immun (1992) 0.93
C-reactive protein and apoB containing lipoproteins are associated with Mycobacterium leprae in lesions of human leprosy. Clin Exp Immunol (1984) 0.92
The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes. Infect Immun (2008) 0.92
Effect of C-reactive protein on the complement-mediated stimulated of human neutrophils by Streptococcus pneumoniae serotypes 3 and 6. Infect Immun (1982) 0.91
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease. PLoS One (2011) 0.86
A computational and experimental study of the regulatory mechanisms of the complement system. PLoS Comput Biol (2011) 0.85
Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase. J Leukoc Biol (2008) 0.84
Evaluation of a C-reactive protein latex agglutination detection test with sera from patients with sexually transmitted diseases. J Clin Microbiol (1984) 0.81
The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection. J Biol Chem (2012) 0.81
Functional effects of CRP binding to nuclei. Immunology (1986) 0.81
C-reactive protein is essential for innate resistance to pneumococcal infection. Immunology (2014) 0.80
Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains. PLoS One (2012) 0.80
C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms. Infect Immun (2015) 0.79
Serum C-Reactive Protein (CRP), Target for Therapy or Trouble? Biomark Insights (2007) 0.77
The Carbohydrate-linked Phosphorylcholine of the Parasitic Nematode Product ES-62 Modulates Complement Activation. J Biol Chem (2016) 0.76
An overview of the synergy and crosstalk between pentraxins and collectins/ficolins: their functional relevance in complement activation. Exp Mol Med (2017) 0.75
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
The chemical composition of pneumococcal C-polysaccharide. J Biol Chem (1963) 3.38
Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med (1971) 3.32
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. Clin Exp Immunol (1971) 1.93
In vitro effects of C-reactive protein on phagocytosis. J Bacteriol (1962) 1.45
Mouse C-reactive protein and endotoxin-induced resistance. J Bacteriol (1965) 1.36
The role of the spleen in experimental pneumococcal bacteremia. J Clin Invest (1981) 1.32
Effect of splenectomy on the susceptibility of mice inoculated with Diplococcus pneumoniae. J Exp Med (1966) 1.17
Degradation of a pneumococcal type-specific polysaccharide with exposure of group-specificity. Proc Natl Acad Sci U S A (1970) 1.15
Mediation of CRP-dependent phagocytosis through mouse macrophage Fc-receptors. J Immunol (1977) 1.14
Studies of human C-reactive protein in an in vitro phagocytic system. J Immunol (1968) 1.10
Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol (1981) 1.06
Complete genome structure of the nitrogen-fixing symbiotic bacterium Mesorhizobium loti. DNA Res (2000) 4.94
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia. Int Arch Allergy Appl Immunol (1967) 2.64
Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc (1981) 2.62
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Capacity of human neutrophils to kill Mycobacterium tuberculosis. J Infect Dis (1987) 2.43
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol (1968) 2.38
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Classification and evolution of EF-hand proteins. Biometals (1998) 2.11
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J Pediatr (1976) 1.98
Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med (1976) 1.95
Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis). Medicine (Baltimore) (1970) 1.94
Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement. Proc Natl Acad Sci U S A (1969) 1.92
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Interactions of the complement system with native and chemically modified endotoxins. J Bacteriol (1968) 1.87
The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med (1999) 1.84
Decreased properdin activity in acute glomerulonephritis. Int Arch Allergy Appl Immunol (1969) 1.83
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
Expression of CD7 antigen precludes t(8;21)(q22;q22) chromosome aberration in acute myeloblastic leukemia. Blood (1992) 1.72
C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67
Complement and complement-like activity in lower vertebrates and invertebrates. J Exp Med (1970) 1.61
Complement-dependent biological functions in complement deficiency in man. Lancet (1966) 1.56
Complement inactivation by serum from patients with acute and hypocomplementemic chronic glomerulonephritis. J Lab Clin Med (1968) 1.54
Mycobacterium leprae fails to stimulate phagocytic cell superoxide anion generation. Infect Immun (1986) 1.52
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology (1974) 1.49
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
yst gene expression in Yersinia enterocolitica is positively regulated by a chromosomal region that is highly homologous to Escherichia coli host factor 1 gene (hfq). Mol Microbiol (1995) 1.48
IgG heavy chain allotypes (Gm) in autoimmune diseases. Clin Exp Immunol (1980) 1.46
Interactions of C-reactive protein with the first component of human complement. J Immunol (1977) 1.45
C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol (1995) 1.44
Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol (2001) 1.44
Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med (1997) 1.43
C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest (2000) 1.42
Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol (2001) 1.41
Decreased C'-1q protein concentration and agglutinating activity in agammaglobulinaemia syndromes: an inborn error reflected in the complement system. Clin Exp Immunol (1968) 1.41
Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol (1976) 1.39
Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol (1975) 1.37
Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg (1969) 1.37
Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet (1969) 1.36
Deficiency of C1r in human serum. Effects on the structure and function of macromolecular C1. J Exp Med (1970) 1.36
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
Complement in endotoxin shock: effect of complement depletion on the early hypotensive phase. Infect Immun (1970) 1.34
Digestive enzymes in insectivorous plants. IV. Enzymatic digestion of insects by Nepenthes secretion and Drosera peltata extract: proteolytic and chitinolytic activities. J Biochem (1972) 1.33
Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci U S A (1982) 1.33
Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol (2000) 1.30
Deficiency of C7 with systemic lupus erythematosus: solubilization of immune complexes in complement-deficient sera. Arthritis Rheum (1981) 1.30
Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol (1987) 1.27
Interactions of the complement system with endotoxins from a Salmonella minnesota mutant deficient in O-polysaccharide and heptose. J Immunol (1968) 1.27
Complement and complement component activities in diseases associated with repeated infections and malignancy. Int Arch Allergy Appl Immunol (1968) 1.27
Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J Immunol (1996) 1.27
Activation and inhibition of IgG mediated complement fixation by staphylococcal protein A. Clin Exp Immunol (1970) 1.27
Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness. Immunology (1977) 1.27
Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology (1975) 1.26
Effect of Mycobacterium tuberculosis-derived sulfolipid I on human phagocytic cells. Infect Immun (1988) 1.25
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation (1967) 1.25
The primary structure of skeletal muscle myosin heavy chain: IV. Sequence of the rod, and the complete 1,938-residue sequence of the heavy chain. J Biochem (1991) 1.22
The complement system in chronic glomerulonephritis: three newly associated aberrations. J Pediatr (1971) 1.21
Localized, aggregative, and diffuse adherence to HeLa cells, plastic, and human small intestines by Escherichia coli isolated from patients with diarrhea. J Infect Dis (1992) 1.20
Ontogenetic development of the complement system. Immunology (1969) 1.19
Complete genome structure of the nitrogen-fixing symbiotic bacterium Mesorhizobium loti (supplement). DNA Res (2000) 1.17
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest (1993) 1.15
Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol (2000) 1.14
Inhibition of platelet aggregation by native and desialised alpha-1 acid glycoprotein. Nature (1979) 1.13
Inhibition of the alternative pathway of human complement by structural analogues of sialic acid. J Immunol (1988) 1.13
Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J Immunol (1975) 1.13
Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol (1993) 1.13
Opsonic properties of C-reactive protein in vivo. J Immunol (1982) 1.13
Studies on the inhibition of C56-initiated lysis (reactive lysis). II. C567-INH--an inhibitor of the C567 trimolecular complex of complement. Int Arch Allergy Appl Immunol (1974) 1.12
Effects of hydrocortisone succinate on the complement system. Nature (1965) 1.11
Interactions of the complement system with endotoxic lipopolysaccharides in immunoglobulin-deficient sera. J Exp Med (1970) 1.11
Binding reactivity of C-reactive protein for polycations. J Immunol (1980) 1.10
The Y chromosome in the liverwort Marchantia polymorpha has accumulated unique repeat sequences harboring a male-specific gene. Proc Natl Acad Sci U S A (2001) 1.10
C-reactive protein reactivity with complement and effects on phagocytosis. Ann N Y Acad Sci (1982) 1.10